Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program is the investigational drug PEGPEH20 (pegvorhyaluronidase alfa).
Halozyme also has value-driving partnerships with leading pharmaceutical and biotechnology companies for our ENHANZE drug delivery technology.